Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2. - sprookjes - yvandenbroek - TriplyDB

Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2.

Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2.

http://www.wikidata.org/entity/Q36350050

about

Purification to homogeneity and partial characterization of cytotoxic lymphocyte maturation factor from human B-lymphoblastoid cells Coexpression of two distinct genes is required to generate secreted bioactive cytotoxic lymphocyte maturation factor Improved systemic delivery of oncolytic reovirus to established tumors using preconditioning with cyclophosphamide-mediated Treg modulation and interleukin-2 The 20th anniversary of interleukin-2 therapy: bimodal role explaining longstanding random induction of complete clinical responses Exploiting a natural conformational switch to engineer an interleukin-2 'superkine'The impact of the myeloid response to radiation therapy Intravenous ascorbic acid as an adjuvant to interleukin-2 immunotherapy Immunotherapy for Bone and Soft Tissue Sarcomas Interferon-gamma reduces melanosomal antigen expression and recognition of melanoma cells by cytotoxic T cells.Left posterior fascicular block due to high-dose interleukin-2.Inability to mediate prolonged reduction of regulatory T Cells after transfer of autologous CD25-depleted PBMC and interleukin-2 after lymphodepleting chemotherapy Effective melanoma immunotherapy in mice by the skin-depigmenting agent monobenzone and the adjuvants imiquimod and CpG.Interleukin 2 prevents graft-versus-host disease while preserving the graft-versus-leukemia effect of allogeneic T cells Lymphokines post autologous peripheral blood stem cell transplantation in children.Immunostimulatory DNA sequences and cancer therapy.Adoptive cell transfer as personalized immunotherapy for human cancer.Immunotherapy for renal carcinoma: theoretical basis and current standard of care.Resveratrol prevents endothelial cells injury in high-dose interleukin-2 therapy against melanoma Pathogenesis of an experimental model of Goodpasture's hemorrhagic pneumonitis Overexpression of interleukin-2 by a recombinant herpes simplex virus type 1 attenuates pathogenicity and enhances antiviral immunity Direct gene transfer with DNA-liposome complexes in melanoma: expression, biologic activity, and lack of toxicity in humans.Immune therapy for breast cancer in 2010-hype or hope?Progress in the development of immunotherapy for the treatment of patients with cancer.Chemical modification of recombinant interleukin 2 by polyethylene glycol increases its potency in the murine Meth A sarcoma model.Development of effective immunotherapy for the treatment of patients with cancer.Additive melanoma suppression with intralesional phospholipid-conjugated TLR7 agonists and systemic IL-2.Increased expression of P-glycoprotein is associated with doxorubicin chemoresistance in the metastatic 4T1 breast cancer model Comparison of adjuvant efficacy of herpes simplex virus type 1 recombinant viruses expressing TH1 and TH2 cytokine genes.The war on cancer: a report from the front lines The mechanisms by which polyamines accelerate tumor spread.Immunotherapy with anti-CD3 monoclonal antibodies and recombinant interleukin 2: stimulation of molecular programs of cytotoxic killer cells and induction of tumor regression.Deciphering the Multifaceted Relationship between Oncolytic Viruses and Natural Killer Cells Application of IL-2 and other cytokines in renal cancer.Cytokines in cancer immunity and immunotherapy.Primary Tumor and MEF Cell Isolation to Study Lung Metastasis.Temporal sequence and cellular origin of interleukin-2 stimulated cytokine gene expression Interleukin-2 inhibits germinal center formation by limiting T follicular helper cell differentiation.Influence of tumour physico-chemical conditions on interleukin-2-stimulated lymphocyte proliferation Interleukin-2 activity can be fine tuned with engineered receptor signaling clamps.Interleukin 2-induced increase of vascular permeability without decrease of the intravascular albumin pool.

P2860

Q24295111-0863C291-20F0-4534-B47D-110F5A30A936 Q24338518-25A0028F-07E4-4E57-A6CE-CE59E87B6869 Q24612603-62BC7445-FF84-40C0-B70F-AFA830C95A6B Q24616434-F13F4632-4C49-4D51-85D1-5CED2A23479E Q24632192-BD54F001-AD39-41F2-9209-6D0E4E42341A Q26851643-E5B6E8C9-9AC4-4CC8-AC0E-0FF7E10D73F9 Q27027097-4DCB72C3-B43F-4491-B94F-F8AB6EF0B472 Q28088363-FC5DF197-DDC7-4995-A312-405B5A10A07B Q30811481-F9B2527F-530F-4736-97D0-D71A4820D429 Q33156492-93F0186C-CABE-4299-A012-2FD524B6CDD4 Q33282703-9C4CD3D9-272E-4EC3-AB7A-F95B89A59A4B Q33586122-41216A3B-8814-4DE0-B5DF-81B5C67C86F8 Q33707814-8ED485A6-3E90-4FD2-B548-1E988BEA83EF Q33847106-B51E724D-8755-412D-96B1-1952DB45B8BE Q34005429-E0A202FA-4860-449A-BF39-F3B5E58E1E4C Q34043643-DA8EA184-1556-4A5A-AF5B-22595E8C36E9 Q34117171-83754B4E-065E-494F-9835-AAF2C9E53B87 Q34245154-497EE8FE-97DB-4FDB-9CE6-4F57607DC28E Q34250688-6927457F-44DC-4CE7-A66B-AB8DEC4F1F7E Q34344404-C1470985-6199-46DC-BD58-5783EC33B79E Q34345458-1D4173B1-72B7-4201-B304-2E59E7EBEA7D Q34541467-7862F6EB-7ABC-42AE-926D-86AC08FDA53C Q34570245-220E1758-80FF-4897-8A97-2AD319475007 Q34604057-37CF1FA7-D213-4EF0-A66D-2E92BFBAC6D8 Q34647354-CDCCEF2D-E669-4395-AFFE-6EFBA06FCB66 Q34672618-CBFCFA38-682D-4FF0-B228-9626E320C5AB Q34755674-9805545D-7F4A-47CE-8FA6-FB2EBDD7A289 Q34976868-50B87D79-7D46-41CA-887C-7562F4230643 Q35103643-1F03C553-B84C-48A6-99A4-F53F8D77AC89 Q35505118-516EC0FC-3947-4DB6-B2A0-63E132AC02D4 Q35670636-AA23F0E4-9876-4687-B21A-41FCA3272E13 Q35687743-EF6D5166-73F6-4415-AA0B-1E8452AA5630 Q35753505-EDA45321-6AB2-4701-834A-1C3FED76DF65 Q35951855-4A008D30-F34C-4CA7-82DD-672BDDC3F6EE Q35974910-260E4ADD-1B8A-4E02-92F0-1E36A5C64553 Q35976007-8123533B-67B2-445E-9817-E605B2BA14B8 Q35991917-20D7E97E-C25C-46A4-AC41-A8676FBCDBE0 Q35993205-3BA4994E-57DC-4B0A-A245-968F646276B7 Q36028807-5124FA89-C6DC-47B4-9E1B-F27319C360E0 Q36079858-EB832971-CCFC-44AE-B8D2-9B94B0CCF7DE

P2860

Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2.

http://www.wikidata.org/entity/Q36350050

description

1985 nî lūn-bûn

@nan

1985年の論文

@ja

1985年学术文章

@wuu

1985年学术文章

@zh-cn

1985年学术文章

@zh-hans

1985年学术文章

@zh-my

1985年学术文章

@zh-sg

1985年學術文章

@yue

1985年學術文章

@zh

1985年學術文章

@zh-hant

name

Regression of established pulm ...... ose recombinant interleukin 2.

@ast

Regression of established pulm ...... ose recombinant interleukin 2.

@en

type

label

Regression of established pulm ...... ose recombinant interleukin 2.

@ast

Regression of established pulm ...... ose recombinant interleukin 2.

@en

prefLabel

Regression of established pulm ...... ose recombinant interleukin 2.

@ast

Regression of established pulm ...... ose recombinant interleukin 2.

@en

P1433

Q36350050-D6A383CF-3964-47D3-A422-0E7FD0EBCDD7

P1476

Q36350050-21180D9E-851D-42DF-917B-70A38A223B93

P2093

Q36350050-37AC6995-97CC-4B96-87A7-517BE19A767D

Q36350050-7D898013-C635-4386-8C02-2B4808F567EB

Q36350050-A9E1FBD2-03F8-48E6-9E02-A54B2E30B958

Q36350050-AE252DE4-03F3-4FFD-AC5C-B4C95D6AB981

Q36350050-E87DAA7F-0A9E-4F27-9EED-4721C2431882

P2860

Q36350050-0E98C392-D3B5-45C1-BDBE-82F42B0E45F0

Q36350050-27DE7649-79B0-482D-BA51-1E8F1F11409E

Q36350050-37234686-4F59-4AEF-B0D9-4C08464165AB

Q36350050-3F67B2E0-EAB0-409F-A892-446A892B647F

Q36350050-5DE92C74-8956-4005-A1AA-90C48202B56C

Q36350050-6A3D07C7-728F-4393-9E63-BE8DC1895C37

Q36350050-732CE615-041F-4EE5-A64D-6E79A8A4FB38

Q36350050-7806923C-5A50-400E-856F-591B5792734D

Q36350050-867B91B2-02AE-4B2A-928B-73923FA9A63D

Q36350050-A06DE7EC-B4F4-4486-925A-097965182992

P304

Q36350050-169071CD-39FC-4EFC-AD30-2420B0B6F695

P31

Q36350050-71135940-78EA-4A81-BA5E-C18ADEEC3C74

P356

Q36350050-9D86227A-ACD4-4E5E-930C-337516103DBC

P407

Q36350050-F2A28298-30E5-4086-8E3A-C7506279D808

P433

Q36350050-9EB73D40-E9D9-436F-82A8-F579373A4C0A

P478

Q36350050-865226A7-AF2E-4326-9780-2C1E184D4CA5

P577

Q36350050-7FF711F0-5454-4BD2-A3ED-9F2373FF0D22

P5875

Q36350050-46AEAD84-ADB3-4EB5-8FC3-94613AF8FC5A

P698

Q36350050-378F72F3-00C8-4F0B-9D42-76E5D6817B4E

P932

Q36350050-AACF6534-FAD4-482F-A728-D5AA6AD86E5D

P356

P1433

Journal of Experimental Medicine

P1476

Regression of established pulm ...... ose recombinant interleukin 2.

@en

P2093

Mulé JJ

http://www.w3.org/2001/XMLSchema#string

Reichert CM

http://www.w3.org/2001/XMLSchema#string

Rosenberg SA

http://www.w3.org/2001/XMLSchema#string

Schwarz SL

http://www.w3.org/2001/XMLSchema#string

Spiess PJ

http://www.w3.org/2001/XMLSchema#string

P2860

Selective in vitro growth of T lymphocytes from normal human bone marrows.

T cell growth factor receptors. Quantitation, specificity, and biological relevance

Augmentation of the anti-tumor therapeutic efficacy of long-term cultured T lymphocytes by in vivo administration of purified interleukin 2.

Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes.

Lymphokine-activated killer cell phenomenon. II. Precursor phenotype is serologically distinct from peripheral T lymphocytes, memory cytotoxic thymus-derived lymphocytes, and natural killer cells.

Successful immunotherapy of natural killer-resistant established pulmonary melanoma metastases by the intravenous adoptive transfer of syngeneic lymphocytes activated in vitro by interleukin 2.

Generation of cytotoxic T lymphocytes to autologous human leukaemia cells by sensitisation to pooled allogeneic normal cells.

In vitro growth of murine T cells. I. Production of factors necessary for T cell growth.

Fetal calf serum-induced blastogenic and cytotoxic responses of human lymphocytes.

Accurate identification of experimental pulmonary metastases.

P304

1169-1188

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1084/JEM.161.5.1169

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

161

http://www.w3.org/2001/XMLSchema#string

P577

1985-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

277453635

http://www.w3.org/2001/XMLSchema#string

P698

3886826

http://www.w3.org/2001/XMLSchema#string

P932

2187617

http://www.w3.org/2001/XMLSchema#string